 |
BioWorld-Insight-2011-08-29
Melanoma Drug Approvals Boost Biotechs' Confidence
CD20 v. CD30: Will SeaGen's Adcetris Be the Next Rituxan?
With this month's FDA approval of Adcetris (brentuximab vedotin), Seattle Genetics Inc. can lay claim to many firsts: first commercial product for the Bothell, Wash.-based biotech, first new drug for Hodgkin lymphoma patients in more than 30 years, first antibody-drug conjugate to gain FDA approval and first anti-CD30-targeted therapy approved. (See BioWorld Today, Aug. 22, 2011.)
Biotech – Big Pharma Collaborations: Modified And Terminated Agreements, July 1 - August 25, 2011
No Abstract
Biotech–Biotech Collaborations: Modified And Terminated Agreements: July 1 - August 25, 2011
No Abstract